CN107028890A - A kind of characteristics of indomethacin solid dispersion - Google Patents
A kind of characteristics of indomethacin solid dispersion Download PDFInfo
- Publication number
- CN107028890A CN107028890A CN201710262850.2A CN201710262850A CN107028890A CN 107028890 A CN107028890 A CN 107028890A CN 201710262850 A CN201710262850 A CN 201710262850A CN 107028890 A CN107028890 A CN 107028890A
- Authority
- CN
- China
- Prior art keywords
- indomethacin
- solid dispersion
- water
- carrier material
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 229960000905 indomethacin Drugs 0.000 title claims abstract description 49
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 32
- 239000012876 carrier material Substances 0.000 claims abstract description 29
- 239000002904 solvent Substances 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 8
- 239000004570 mortar (masonry) Substances 0.000 claims abstract description 8
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229920003081 Povidone K 30 Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 18
- 239000003960 organic solvent Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 description 15
- 238000011010 flushing procedure Methods 0.000 description 6
- CUXQLKLUPGTTKL-UHFFFAOYSA-M microcosmic salt Chemical compound [NH4+].[Na+].OP([O-])([O-])=O CUXQLKLUPGTTKL-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000001934 delay Effects 0.000 description 5
- 239000012738 dissolution medium Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000012982 microporous membrane Substances 0.000 description 5
- 238000005096 rolling process Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of characteristics of indomethacin solid dispersion, belongs to technical field of medicine, is made up of following preparation methods：Water-soluble carrier material is added in solvent, is stirred to dissolve, is then added Indomethacin, it is stirred to dissolve, rotary evaporation eliminates organic solvent after stirring at low speed 1h, residue is dried under reduced pressure 12~24h in an oven, ground after drying in mortar, cross 80 mesh sieves, produce characteristics of indomethacin solid dispersion.The present invention can effectively improve the solubility and dissolution rate of Indomethacin, so as to effectively improve the bioavilability of Indomethacin.
Description
Technical field
The present invention relates to technical field of medicine, more particularly to a kind of characteristics of indomethacin solid dispersion.
Background technology
Indomethacin chemistry is entitled：2- methyl isophthalic acids-(4- chlorobenzene formacyls) -5- methoxyl group -1H- indole-3-acetic acids, molecule
Formula is C19H16ClNO4, molecular weight is 357.79, structural formula such as following formula：
Indomethacin is white or slightly yellow crystalline powder, and fusing point is 158~162 DEG C, is dissolved in acetone, is slightly soluble in second
Alcohol, chloroform, ether, are practically insoluble in water, tasteless, almost odorless.
Indomethacin has anti-inflammatory, antipyretic and analgesic activity, and its mechanism of action is subtracts by the suppression to Cycloxygenase
The synthesis of few prostaglandin, prevents the formation of inflammatory tissue pain nerve impulsion, suppresses inflammatory reaction, including suppress leucocyte
Release of chemotaxis and lysosomal enzyme etc..It is due to that it acts on hypothalamus heat-regulating centers as antipyretic effect, causes outer
All blood vessel dilatation and perspiration, increase radiating, and this central antipyretic effect may also be synthesized with the prostaglandin in hypothalamus
It is suppressed relevant.The acute toxicity tests：Rat oral LD50For 12mg/kg；Its mouse oral LD5For 50mg/kg.
Indoles U.S. Yin is practically insoluble in water, is insoluble drug, insoluble drug (poorly water-soluble
Drug) solubility is small in water, and medicine is difficult to be absorbed by organisms, and internal release rate is very fast, and peak valley easily occurs in blood concentration
Phenomenon, oral formulations bioavilability is low, and is difficult to the variation of formulation.The absorption rate of insoluble drug generally depends on
In dissolution rate, dissolution rate is improved with the raising of decentralization.
The content of the invention
The invention provides a kind of characteristics of indomethacin solid dispersion, existing Indomethacin preparation dissolution rate is solved relatively low
Problem.
In order to solve the above technical problems, the technical scheme is that：
A kind of characteristics of indomethacin solid dispersion, is made up of following preparation methods：Water-soluble carrier material adds solvent
In, it is stirred to dissolve, then adds Indomethacin, be stirred to dissolve, rotary evaporation eliminates organic solvent after stirring at low speed 1h, remains
Excess is dried under reduced pressure 12~24h in an oven, is ground after drying in mortar, crosses 80 mesh sieves, produces Indomethacin solid and disperses
Body.
Wherein it is preferred to, the water soluble carrier material is PVP K30, polyethylene glycol, PVPP
Any one of polyethylene glycol oxide carboxymethyl cellulose.
Wherein it is preferred to, the solvent is that volume ratio is 2：1 second alcohol and water, volume ratio are 2:1 first alcohol and water or body
Product is than being 2:1 acetone and water.
Wherein it is preferred to, the temperature control being dried under reduced pressure is at 45~55 DEG C.
Wherein it is preferred to, the usage ratio of the water soluble carrier material and the solvent is 1g：5~7ml.
Wherein it is preferred to, the weight ratio of the water soluble carrier material and the Indomethacin is 2~3:1.
Beneficial effect of the present invention：
The present invention can effectively improve the solubility and dissolution rate of Indomethacin, beautiful so as to effectively improve indoles
Pungent bioavilability.
In Vitro Dissolution, which is tested, to be shown, solid dispersions prepared by the present invention, compared with the Indomethacin with crystalline state, in 0.1M
In hydrochloric acid solution, pH 4.5, pH 6.0 and pH 7.4 microcosmic salt buffer solution, the water solubility of Indomethacin is improved, and has
Higher dissolution rate.
Brief description of the drawings
In order to illustrate more clearly about the embodiment of the present invention or technical scheme of the prior art, below will be to embodiment or existing
There is the accompanying drawing used required in technology description to be briefly described, it should be apparent that, drawings in the following description are only this
Some embodiments of invention, for those of ordinary skill in the art, without having to pay creative labor, may be used also
To obtain other accompanying drawings according to these accompanying drawings.
Fig. 1 is the stripping curve figure of the embodiment of the present invention 1；
Fig. 2 is the stripping curve figure of the embodiment of the present invention 2；
Fig. 3 is the stripping curve figure of the embodiment of the present invention 3；
Fig. 4 is the stripping curve figure of the embodiment of the present invention 4；
Fig. 5 is the stripping curve figure of the embodiment of the present invention 5.
Embodiment
Below in conjunction with the specific embodiment of the invention, the technical scheme to the present invention carries out clear, complete description, institute
The example of description is only the section Example of the present invention, rather than whole embodiments.Based on the embodiment in the present invention, sheet
Field those of ordinary skill, the every other embodiment obtained under the premise of creative work is not made, belongs to this hair
Bright protection domain.
Embodiment 1
The present embodiment provides a kind of characteristics of indomethacin solid dispersion, is made up of following preparation methods：Water-soluble carrier
Material is added in solvent, is stirred to dissolve, is then added Indomethacin, be stirred to dissolve, rotary evaporation is removed after stirring at low speed 1h
Most organic solvent, residue is dried under reduced pressure 18h for 45~55 DEG C in an oven, is ground after drying in mortar, crosses 80 mesh sieves, produces
Characteristics of indomethacin solid dispersion.
Wherein, the water soluble carrier material is PVP K30.
Wherein, the solvent is that volume ratio is 2：1 second alcohol and water.
Wherein, the usage ratio of the water soluble carrier material and the solvent is 1g：6ml.
Wherein, the weight ratio of the water soluble carrier material and the Indomethacin is 2.5:1.
The sample and bulk drug for taking the above method to prepare, are placed in wide-mouth bottle, and the microcosmic salt for adding 200m L pH 7.4 delays
Fliud flushing is as dissolution medium, rolling of being shaken in 37 DEG C of shaking tables, in different time points sampling, through filtering with microporous membrane, surveys its absorbance,
The solubility of comparative sample.Stripping curve figure is as shown in Figure 1.
It can be seen from Fig. 1 stripping curve compared with bulk drug, the dissolution rate and dissolution rate of solid dispersions have
It is obvious to improve.
Embodiment 2
The present embodiment provides a kind of characteristics of indomethacin solid dispersion, is made up of following preparation methods：Water-soluble carrier
Material is added in solvent, is stirred to dissolve, is then added Indomethacin, be stirred to dissolve, rotary evaporation is removed after stirring at low speed 1h
Most organic solvent, residue is dried under reduced pressure 12h for 45~55 DEG C in an oven, is ground after drying in mortar, crosses 80 mesh sieves, produces
Characteristics of indomethacin solid dispersion.
Wherein, the water soluble carrier material is polyethylene glycol.
Wherein, the solvent is that volume ratio is 2:1 first alcohol and water.
Wherein, the usage ratio of the water soluble carrier material and the solvent is 1g：5ml.
Wherein, the weight ratio of the water soluble carrier material and the Indomethacin is 3:1.
The sample and bulk drug for taking the above method to prepare, are placed in wide-mouth bottle, and the microcosmic salt for adding 200m L pH 7.4 delays
Fliud flushing is as dissolution medium, rolling of being shaken in 37 DEG C of shaking tables, in different time points sampling, through filtering with microporous membrane, surveys its absorbance,
The solubility of comparative sample.Stripping curve figure is as shown in Figure 2.
It can be seen from Fig. 2 stripping curve compared with bulk drug, the dissolution rate and dissolution rate of solid dispersions have
It is obvious to improve.
Embodiment 3
The present embodiment provides a kind of characteristics of indomethacin solid dispersion, is made up of following preparation methods：Water-soluble carrier
Material is added in solvent, is stirred to dissolve, is then added Indomethacin, be stirred to dissolve, rotary evaporation is removed after stirring at low speed 1h
Most organic solvent, residue is dried under reduced pressure 24h for 45~55 DEG C in an oven, is ground after drying in mortar, crosses 80 mesh sieves, produces
Characteristics of indomethacin solid dispersion.
Wherein, the water soluble carrier material is PVPP.
Wherein, the solvent is that volume ratio is that volume ratio is 2:1 acetone and water.
Wherein, the usage ratio of the water soluble carrier material and the solvent is 1g：7ml.
Wherein, the weight ratio of the water soluble carrier material and the Indomethacin is 2:1.
The sample and bulk drug for taking the above method to prepare, are placed in wide-mouth bottle, and the microcosmic salt for adding 200m L pH 7.4 delays
Fliud flushing is as dissolution medium, rolling of being shaken in 37 DEG C of shaking tables, in different time points sampling, through filtering with microporous membrane, surveys its absorbance,
The solubility of comparative sample.Stripping curve figure is as shown in Figure 3.
It can be seen from Fig. 3 stripping curve compared with bulk drug, the dissolution rate and dissolution rate of solid dispersions have
It is obvious to improve.
Embodiment 4
The present embodiment provides a kind of characteristics of indomethacin solid dispersion, is made up of following preparation methods：Water-soluble carrier
Material is added in solvent, is stirred to dissolve, is then added Indomethacin, be stirred to dissolve, rotary evaporation is removed after stirring at low speed 1h
Most organic solvent, residue is dried under reduced pressure 16h for 45~55 DEG C in an oven, is ground after drying in mortar, crosses 80 mesh sieves, produces
Characteristics of indomethacin solid dispersion.
Wherein, the water soluble carrier material is polyethylene glycol oxide.
Wherein, the solvent is that volume ratio is 2：1 second alcohol and water.
Wherein, the usage ratio of the water soluble carrier material and the solvent is 1g：6ml.
Wherein, the weight ratio of the water soluble carrier material and the Indomethacin is 2.6:1.
The sample and bulk drug for taking the above method to prepare, are placed in wide-mouth bottle, and the microcosmic salt for adding 200m L pH 7.4 delays
Fliud flushing is as dissolution medium, rolling of being shaken in 37 DEG C of shaking tables, in different time points sampling, through filtering with microporous membrane, surveys its absorbance,
The solubility of comparative sample.Stripping curve figure is as shown in Figure 4.
It can be seen from Fig. 4 stripping curve compared with bulk drug, the dissolution rate and dissolution rate of solid dispersions have
It is obvious to improve.
Embodiment 5
The present embodiment provides a kind of characteristics of indomethacin solid dispersion, is made up of following preparation methods：Water-soluble carrier
Material is added in solvent, is stirred to dissolve, is then added Indomethacin, be stirred to dissolve, rotary evaporation is removed after stirring at low speed 1h
Most organic solvent, residue is dried under reduced pressure 20h for 45~55 DEG C in an oven, is ground after drying in mortar, crosses 80 mesh sieves, produces
Characteristics of indomethacin solid dispersion.
Wherein, the water soluble carrier material is carboxymethyl cellulose.
Wherein, the solvent is that volume ratio is 2:1 acetone and water.
Wherein, the usage ratio of the water soluble carrier material and the solvent is 1g：7ml.
Wherein, the weight ratio of the water soluble carrier material and the Indomethacin is 2：1.
The sample and bulk drug for taking the above method to prepare, are placed in wide-mouth bottle, and the microcosmic salt for adding 200m L pH 7.4 delays
Fliud flushing is as dissolution medium, rolling of being shaken in 37 DEG C of shaking tables, in different time points sampling, through filtering with microporous membrane, surveys its absorbance,
The solubility of comparative sample.Stripping curve figure is as shown in Figure 5.
It can be seen from Fig. 5 stripping curve compared with bulk drug, the dissolution rate and dissolution rate of solid dispersions have
It is obvious to improve.
Solid dispersions made from above-described embodiment equally also delay in 0.1N hydrochloric acid solutions, pH 4.5, the phosphate of pH 6.0
Make Dissolution Rate Testing in fliud flushing, as a result show, solid dispersions produced by the present invention are compared with bulk drug, dissolution rate and dissolution
Degree is also what is significantly improved.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
God is with principle, and any modification, equivalent substitution and improvements made etc. should be included in the scope of the protection.
Claims (6)
1. a kind of characteristics of indomethacin solid dispersion, it is characterised in that be made up of following preparation methods：Water-soluble carrier material
Add in solvent, be stirred to dissolve, then add Indomethacin, be stirred to dissolve, rotary evaporation has been eliminated after stirring at low speed 1h
Machine solvent, residue is dried under reduced pressure 12~24h in an oven, is ground after drying in mortar, crosses 80 mesh sieves, produces Indomethacin
Solid dispersions.
2. a kind of characteristics of indomethacin solid dispersion according to claim 1, it is characterised in that：The water soluble carrier material
For any one of PVP K30, polyethylene glycol, PVPP, polyethylene glycol oxide, carboxymethyl cellulose.
3. a kind of characteristics of indomethacin solid dispersion according to claim 1, it is characterised in that：The solvent is that volume ratio is
2：1 second alcohol and water, volume ratio are 2:1 first alcohol and water or volume ratio is 2:1 acetone and water.
4. a kind of characteristics of indomethacin solid dispersion according to claim 1, it is characterised in that：The temperature being dried under reduced pressure
Control is at 45~55 DEG C.
5. a kind of characteristics of indomethacin solid dispersion according to claim 1, it is characterised in that：The water soluble carrier material
Usage ratio with the solvent is 1g：5~7ml.
6. a kind of characteristics of indomethacin solid dispersion according to claim 1, it is characterised in that：The water soluble carrier material
Weight ratio with the Indomethacin is 2~3:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710262850.2A CN107028890A (en) | 2017-04-20 | 2017-04-20 | A kind of characteristics of indomethacin solid dispersion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710262850.2A CN107028890A (en) | 2017-04-20 | 2017-04-20 | A kind of characteristics of indomethacin solid dispersion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107028890A true CN107028890A (en) | 2017-08-11 |
Family
ID=59536433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710262850.2A Pending CN107028890A (en) | 2017-04-20 | 2017-04-20 | A kind of characteristics of indomethacin solid dispersion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107028890A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111658615A (en) * | 2020-07-31 | 2020-09-15 | 青岛科技大学 | Indometacin nano particle and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732233A (en) * | 2009-11-19 | 2010-06-16 | 浙江工业大学 | Method for preparing solid dispersion |
| WO2010133611A1 (en) * | 2009-05-18 | 2010-11-25 | Royal College Of Surgeons In Ireland | Solid drug dispersions |
| CN106138006A (en) * | 2015-03-26 | 2016-11-23 | 天津药物研究院有限公司 | A kind of capsule containing characteristics of indomethacin solid dispersion and preparation method thereof |
-
2017
- 2017-04-20 CN CN201710262850.2A patent/CN107028890A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010133611A1 (en) * | 2009-05-18 | 2010-11-25 | Royal College Of Surgeons In Ireland | Solid drug dispersions |
| CN101732233A (en) * | 2009-11-19 | 2010-06-16 | 浙江工业大学 | Method for preparing solid dispersion |
| CN106138006A (en) * | 2015-03-26 | 2016-11-23 | 天津药物研究院有限公司 | A kind of capsule containing characteristics of indomethacin solid dispersion and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 唐岚等: "厚朴酚-交联羧甲基纤维素钠固体分散体的制备及体外溶出研究", 《中国中药杂志》 * |
| 张奇编: "《军用药物制剂工程学》", 30 April 2012, 北京理工大学出版社 * |
| 张青等: "吲哚美辛固体分散体的制备和理化性质的研究", 《中国医院药学杂志》 * |
| 易军主编: "《药剂学复习指南》", 31 January 2014, 天津科技翻译出版有限公司 * |
| 罗明生等主编: "《药剂辅料大全》", 31 January 2006, 四川科学技术出版社 * |
| 范仁峰: "吲哚美辛固体分散体及其肠溶片的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111658615A (en) * | 2020-07-31 | 2020-09-15 | 青岛科技大学 | Indometacin nano particle and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101869113B (en) | Cyclodextrin inclusion compound of rodents sterilant and preparation method thereof | |
| JP5087086B2 (en) | Drug composition containing inclusion body of cyclodextrin / paclitaxel and method for producing the same | |
| JP6693999B2 (en) | Transdermal absorption enhancer and transdermal absorption enhancer | |
| CN109432013B (en) | Florfenicol soluble powder and preparation method thereof | |
| KR20150023059A (en) | Racecadotril liquid compositions | |
| Sui et al. | Self-assembly of an amphiphilic derivative of chitosan and micellar solubilization of puerarin | |
| CN102240268A (en) | Sustained/controlled release microsphere of biological extract Genipin cross-linked chitosan coated stilbene compound and preparation method thereof | |
| CN101519475B (en) | Preparation method of rotenone/carboxymethyl chitosan grafted ricinoleic acid nanoparticle water dispersion preparation | |
| CN107028890A (en) | A kind of characteristics of indomethacin solid dispersion | |
| CN108379593A (en) | A method of preparing Florfenicol-chitosan/long-chain carboxylic acid's nano-micelle freeze-dried powder | |
| CN107661505A (en) | Hinokitiol inclusion compound and preparation method thereof | |
| TW200621310A (en) | A process for preparing formulations of lypophilic active substances by spray freeze drying | |
| JP6480866B2 (en) | Method for selectively producing D-mannitol α-type crystal using spray drying method | |
| CN107080743A (en) | A kind of capsule containing characteristics of indomethacin solid dispersion | |
| CN109846865A (en) | A kind of curcumin preparation and preparation method thereof | |
| CN105315282A (en) | Preparation method of ticagrelor amorphous form | |
| EP1140197B1 (en) | Soluble compositions of toremifene | |
| CN1853627B (en) | Cyclodextrin of bibenziisosehenazole ethane or cyclodextrin derivative inclusion compound, and preparation and use thereof | |
| RU2389491C2 (en) | Complex containing mequitazine, cyclodextrin and reaction agent | |
| CN111330019A (en) | Flumazenil inclusion compound and preparation method and application thereof | |
| JP2001261559A (en) | High-concentration vitamin c composition and method for preparing the same | |
| CN101617827A (en) | Supramolecular composite of isosteviol or derivative thereof and preparation method thereof | |
| CN101314046B (en) | Cyclodextrin inclusion method for hair orchid native | |
| CN101322845B (en) | Erianin inclusion compound | |
| WO2024174356A1 (en) | Spinosad microcapsule powder and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170811 |